Cargando…

Cancer Cell–Membrane Biomimetic Boron Nitride Nanospheres for Targeted Cancer Therapy

PURPOSE: Nanomaterial-based drug-delivery systems allowing for effective targeted delivery of smallmolecule chemodrugs to tumors have revolutionized cancer therapy. Recently, as novel nanomaterials with outstanding physicochemical properties, boron nitride nanospheres (BNs) have emerged as a promisi...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Shini, Ren, Yajing, Li, Hui, Tang, Yunfei, Yan, Jinyu, Shen, Zeyuan, Zhang, Huijie, Chen, Fuxue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959002/
https://www.ncbi.nlm.nih.gov/pubmed/33731994
http://dx.doi.org/10.2147/IJN.S266948
_version_ 1783664898953183232
author Feng, Shini
Ren, Yajing
Li, Hui
Tang, Yunfei
Yan, Jinyu
Shen, Zeyuan
Zhang, Huijie
Chen, Fuxue
author_facet Feng, Shini
Ren, Yajing
Li, Hui
Tang, Yunfei
Yan, Jinyu
Shen, Zeyuan
Zhang, Huijie
Chen, Fuxue
author_sort Feng, Shini
collection PubMed
description PURPOSE: Nanomaterial-based drug-delivery systems allowing for effective targeted delivery of smallmolecule chemodrugs to tumors have revolutionized cancer therapy. Recently, as novel nanomaterials with outstanding physicochemical properties, boron nitride nanospheres (BNs) have emerged as a promising candidate for drug delivery. However, poor dispersity and lack of tumor targeting severely limit further applications. In this study, cancer cell–membrane biomimetic BNs were designed for targeted anticancer drug delivery. METHODS: Cell membrane extracted from HeLa cells (HM) was used to encapsulate BNs by physical extrusion. Doxorubicin (Dox) was loaded onto HM-BNs as a model drug. RESULTS: The cell-membrane coating endowed the BNs with excellent dispersibility and cytocompatibility. The drug-release profile showed that the Dox@HM-BNs responded to acid pH, resulting in rapid Dox release. Enhanced cellular uptake of Dox@HM-BNs by HeLa cells was revealed because of the homologous targeting of cancer-cell membranes. CCK8 and live/dead assays showed that Dox@HM-BNs had stronger cytotoxicity against HeLa cells, due to self-selective cellular uptake. Finally, antitumor investigation using the HeLa tumor model demonstrated that Dox@HM-BNs possessed much more efficient tumor inhibition than free Dox or Dox@BNs. CONCLUSION: These findings indicate that the newly developed HM-BNs are promising as an efficient tumor-selective drug-delivery vehicle for tumor therapy.
format Online
Article
Text
id pubmed-7959002
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-79590022021-03-16 Cancer Cell–Membrane Biomimetic Boron Nitride Nanospheres for Targeted Cancer Therapy Feng, Shini Ren, Yajing Li, Hui Tang, Yunfei Yan, Jinyu Shen, Zeyuan Zhang, Huijie Chen, Fuxue Int J Nanomedicine Original Research PURPOSE: Nanomaterial-based drug-delivery systems allowing for effective targeted delivery of smallmolecule chemodrugs to tumors have revolutionized cancer therapy. Recently, as novel nanomaterials with outstanding physicochemical properties, boron nitride nanospheres (BNs) have emerged as a promising candidate for drug delivery. However, poor dispersity and lack of tumor targeting severely limit further applications. In this study, cancer cell–membrane biomimetic BNs were designed for targeted anticancer drug delivery. METHODS: Cell membrane extracted from HeLa cells (HM) was used to encapsulate BNs by physical extrusion. Doxorubicin (Dox) was loaded onto HM-BNs as a model drug. RESULTS: The cell-membrane coating endowed the BNs with excellent dispersibility and cytocompatibility. The drug-release profile showed that the Dox@HM-BNs responded to acid pH, resulting in rapid Dox release. Enhanced cellular uptake of Dox@HM-BNs by HeLa cells was revealed because of the homologous targeting of cancer-cell membranes. CCK8 and live/dead assays showed that Dox@HM-BNs had stronger cytotoxicity against HeLa cells, due to self-selective cellular uptake. Finally, antitumor investigation using the HeLa tumor model demonstrated that Dox@HM-BNs possessed much more efficient tumor inhibition than free Dox or Dox@BNs. CONCLUSION: These findings indicate that the newly developed HM-BNs are promising as an efficient tumor-selective drug-delivery vehicle for tumor therapy. Dove 2021-03-11 /pmc/articles/PMC7959002/ /pubmed/33731994 http://dx.doi.org/10.2147/IJN.S266948 Text en © 2021 Feng et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Feng, Shini
Ren, Yajing
Li, Hui
Tang, Yunfei
Yan, Jinyu
Shen, Zeyuan
Zhang, Huijie
Chen, Fuxue
Cancer Cell–Membrane Biomimetic Boron Nitride Nanospheres for Targeted Cancer Therapy
title Cancer Cell–Membrane Biomimetic Boron Nitride Nanospheres for Targeted Cancer Therapy
title_full Cancer Cell–Membrane Biomimetic Boron Nitride Nanospheres for Targeted Cancer Therapy
title_fullStr Cancer Cell–Membrane Biomimetic Boron Nitride Nanospheres for Targeted Cancer Therapy
title_full_unstemmed Cancer Cell–Membrane Biomimetic Boron Nitride Nanospheres for Targeted Cancer Therapy
title_short Cancer Cell–Membrane Biomimetic Boron Nitride Nanospheres for Targeted Cancer Therapy
title_sort cancer cell–membrane biomimetic boron nitride nanospheres for targeted cancer therapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959002/
https://www.ncbi.nlm.nih.gov/pubmed/33731994
http://dx.doi.org/10.2147/IJN.S266948
work_keys_str_mv AT fengshini cancercellmembranebiomimeticboronnitridenanospheresfortargetedcancertherapy
AT renyajing cancercellmembranebiomimeticboronnitridenanospheresfortargetedcancertherapy
AT lihui cancercellmembranebiomimeticboronnitridenanospheresfortargetedcancertherapy
AT tangyunfei cancercellmembranebiomimeticboronnitridenanospheresfortargetedcancertherapy
AT yanjinyu cancercellmembranebiomimeticboronnitridenanospheresfortargetedcancertherapy
AT shenzeyuan cancercellmembranebiomimeticboronnitridenanospheresfortargetedcancertherapy
AT zhanghuijie cancercellmembranebiomimeticboronnitridenanospheresfortargetedcancertherapy
AT chenfuxue cancercellmembranebiomimeticboronnitridenanospheresfortargetedcancertherapy